This article is for educational purposes only. Always consult your healthcare provider before starting, stopping, or changing GLP-1 medication.
Mounjaro and Zepbound contain the exact same active ingredient — tirzepatide — developed and manufactured by Eli Lilly. Same molecule, same injection pen, same dosing intervals. If that sounds familiar, it should: this is the same situation as Ozempic and Wegovy (both semaglutide from Novo Nordisk), but with a different manufacturer and a drug that works through a somewhat different mechanism.
Why does one molecule get two brand names? The answer is commercial and regulatory, not scientific. FDA approval pathways are indication-specific — one label for type 2 diabetes, one for obesity — and separate labeling creates separate insurance, formulary, and pricing tracks.
Understanding the distinction helps you navigate the system, access the right savings programs, and have productive conversations with your prescriber.
What Is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its kind. It activates both glucagon-like peptide-1 (GLP-1) receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors simultaneously. This dual action is what distinguishes tirzepatide from semaglutide and earlier GLP-1 medications.
GIP, like GLP-1, is an incretin hormone released after eating. It stimulates insulin secretion, reduces appetite, and appears to have direct effects on adipose (fat) tissue. The combination of GLP-1 and GIP activity may explain why tirzepatide produces, on average, larger weight loss than semaglutide at their respective maximum doses — though no head-to-head trial directly comparing the two at maximum approved doses has been published.
Mounjaro: The Diabetes Indication
Mounjaro received FDA approval for type 2 diabetes in May 2022. The approval was based on the SURPASS clinical trial program, a series of trials comparing tirzepatide to placebo and to active comparators including semaglutide (Ozempic 1 mg) and insulin degludec.
In SURPASS-2, tirzepatide 15 mg produced an average HbA1c reduction of 2.46 percentage points and a mean weight loss of 12.4 kg (27.3 lbs) in patients with type 2 diabetes — significantly better than semaglutide 1 mg comparator.
Approved doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly injection) Starting dose: 2.5 mg for 4 weeks, then 5 mg, escalating every 4 weeks as tolerated
Zepbound: The Obesity Indication
Zepbound received FDA approval for chronic weight management in November 2023, making it one of the most recently approved anti-obesity medications. The approval was based on the SURMOUNT trial program.
In SURMOUNT-1 — the pivotal trial — adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition achieved:
- 15 mg dose: Average 22.5% body weight loss (~52 lbs for a 230-lb person) over 72 weeks
- 10 mg dose: Average 21.4% body weight loss
- 5 mg dose: Average 16.0% body weight loss
These are the largest weight loss results reported in any Phase 3 randomized controlled trial for an obesity medication — a remarkable benchmark that has reshaped clinical expectations for pharmacological weight management.
Approved doses: Same as Mounjaro: 2.5 mg through 15 mg weekly Starting dose: 2.5 mg for 4 weeks, escalating
Side-by-Side Comparison
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA indication | Type 2 diabetes | Obesity/weight management; CVD risk reduction |
| Approval year | 2022 | 2023 |
| Dose range | 2.5 mg – 15 mg | 2.5 mg – 15 mg |
| Injection | Once weekly, subcutaneous | Once weekly, subcutaneous |
| Pen device | KwikPen | KwikPen (identical) |
| Savings card availability | Yes (for diabetes patients) | Yes (for obesity patients) |
| List price/month (approx.) | ~$1,069 | ~$1,059 |
| Medicare coverage | Part D (diabetes) | Limited; depends on plan |
Insurance Coverage: The Decisive Factor
As with the Ozempic/Wegovy situation, insurance coverage is often the deciding factor in which brand you receive.
Mounjaro Coverage
Mounjaro has been on commercial insurance formularies for type 2 diabetes since 2022. Most major payers with diabetes coverage include it. Medicare Part D covers Mounjaro for diabetes. Eli Lilly's Mounjaro savings card can reduce cost to $25–$550/month for eligible commercially insured patients, depending on their plan tier.
Zepbound Coverage
Obesity medications have historically faced coverage challenges. However, Zepbound's trajectory is improving:
- In 2024, Eli Lilly launched a self-pay program for Zepbound through its LillyDirect platform, allowing patients to pay directly for certain doses without insurance, starting at approximately $349–$499/month for lower doses.
- Several large self-insured employers have added Zepbound to their formularies since 2024, driven by health plan ROI data on obesity medication.
- Medicare coverage of Zepbound specifically for obesity remains limited as of 2026.
- Eli Lilly offers a Zepbound savings card that can reduce commercially insured costs substantially for qualifying patients.
Off-Label Use of Mounjaro for Weight Loss
Before Zepbound's approval, Mounjaro was frequently prescribed off-label for weight management in patients without diabetes — a pattern nearly identical to the Ozempic/Wegovy situation. This practice declined after Zepbound's November 2023 approval but persists in cases where:
- A patient's insurance covers Mounjaro for diabetes but not Zepbound for obesity
- Supply issues affect one product
- A prescriber prefers one product for a specific clinical reason
If you're using Mounjaro off-label for weight loss, be aware that Eli Lilly's Mounjaro savings program is designed for diabetes patients and may not apply to off-label use.
The Cardiovascular Indication for Zepbound
In late 2024, the FDA approved an additional indication for Zepbound for reducing cardiovascular risk in adults with obesity or overweight with established cardiovascular disease — mirroring the SELECT-driven expansion of Wegovy's label. This is clinically important and may further improve payer coverage, as cardiovascular indications face fewer coverage exclusions than pure obesity indications.
Compounded Tirzepatide
Following supply shortages, the FDA permitted compounding pharmacies to produce copies of tirzepatide under shortage designations. As of 2025–2026, the shortage status of Mounjaro and Zepbound has changed multiple times. Compounded tirzepatide can be significantly less expensive (sometimes $150–$300/month) but:
- Is not FDA-approved and not subject to the same quality standards as the branded products
- Has variable potency and purity across compounding pharmacies
- Cannot legally contain the same active pharmaceutical ingredient when the branded products are off the shortage list
- Should only be used under medical supervision from a licensed provider
Check with your prescriber and verify the FDA's current shortage designations at fda.gov/drugs/drug-safety-and-availability/drug-shortages before pursuing compounded options.
Use our cost estimator to compare current pricing scenarios for Mounjaro, Zepbound, and alternatives.
Which One Will You Actually Receive?
In practice, the determining factors are:
- Your diagnosis. If you have type 2 diabetes, your prescriber will likely prescribe Mounjaro. If you have obesity without diabetes, Zepbound is the indicated option.
- Your insurance. Some plans cover one but not the other, or have different tier placements.
- Your prescriber's judgment. In cases where both could be indicated, your provider will factor in clinical context, access, and cost.
- Supply. Both products have experienced periodic supply constraints. Your pharmacy may have one in stock and not the other.
From a clinical effectiveness standpoint, there is no reason to prefer one over the other — they are pharmacologically identical.
Sources
- Joshi SR, et al. "SURMOUNT-1: Tirzepatide vs. Placebo for Obesity." NEJM, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)." NEJM, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
- FDA. "Mounjaro (tirzepatide) Prescribing Information." https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
- FDA. "Zepbound (tirzepatide) Prescribing Information." https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
- Eli Lilly. "Zepbound (tirzepatide) Prescribing Information (FDA approval letter)." https://pi.lilly.com/us/zepbound-uspi.pdf
- FDA Drug Shortages Database. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages